Raymond James downgrades Sionna Therapeutics stock rating on trial failure

Raymond James has downgraded Sionna Therapeutics to Market Perform from Outperform after the company's Phase 2a trial for SION-719 in combination with Trikafta failed to meet its primary endpoint, showing only a 1.0 mmol/L sweat chloride reduction against a target of 10 mmol/L. This trial failure, attributed partly to drug-drug interaction issues, has significantly impacted the stock, which is trading near its 52-week low. Despite previous optimism from Raymond James, the extended timelines for a competitive combination therapy have led to the downgrade, following similar actions by Wedbush and Stifel.